GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Potential mechanisms for the cardio-nephroprotective effect of GLP-1RA (modified from: Thomas [39] and Greco [40].](https://figures.cochat.ai/paper-figures/c8d9da03e9824ec9909616812b8e0d61/glp-1-receptor-agonists-and-diabetic-kidney-disease-a-call-of-attention-to-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exendin-4 analogues are resistant to inactivation of dipeptidyl peptidase-4, while GLP-1 analogues are partially metabolized to metabolites, which may be related to the better benefits in cardioprotective effects of liraglutide than exenatide [80, 81].”
The cited source says what the claim attributes to it.
In the citing paper
“However, exendin-4 analogues are metabolized and eliminated by the kidneys.”
In the citing paper
“Their large molecular size or noncovalent attachment to albumin can prevent them from being eliminated by the kidneys.”
In the citing paper
“It was believed that GLP-1 analogues are metabolized in target tissues via the common proteolytic pathway of large proteins.”
In the citing paper
“Moreover, exendin-4 analogues are resistant to inactivation of dipeptidyl peptidase-4, while GLP-1 analogues are partially metabolized to metabolites, which may be related to the better benefits in cardioprotective effects of liraglutide than exenatide [80, 81].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“(liraglutide) [19,52], SUSTAIN 6 (subcutaneous semaglutide) [20], HARMONY (albiglutide) [53], REWIND (dulaglutide) [37], PIONEER 6 (oral semaglutide) [54] and FREEDOM-CVO (ITCA 650, a novel drug device delivering continuous exenatide) [55] (See Table 2, Figure 2).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 13×
“5 or 1 mg of long-acting semaglutide in 3297 T2DM patients at high risk for CV risk, defined by age 50 or older with established cardiovascular disease, chronic heart failure (New York Heart Association class II or III), or CKD stage 3 or higher or age 60 or older with at least one cardiovascular risk factor [20].”
BackgroundInfluentialDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“73 m2, even when the drug was maintained until the initiation of dialysis [16,18].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 2,994
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 3×
“Until recently, prevention of DKD progression was based on strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors (dyslipidemia, obesity and smoking), as well as nephrotoxic drug avo…”
BackgroundMethodLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 15×
“outcomes in 60,090 T2DM patients: ELIXA (lixisenatide) [50], EXSCEL (exenatide) [51], LEADER”
BackgroundResultInfluential
Research works printed but not linked: 1
- 2019, New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus, Hipertens. Riesgo Vasc., 36, 145
Cited by
Gupta, S., Dominguez, M., & Golestaneh, L. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.004 · Cited by 337
Yamada, T., Wakabayashi, M., Bhalla, A., Chopra, N., Miyashita, H., Mikami, T., Ueyama, H., Fujisaki, T., Saigusa, Y., Yamaji, T., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01197-z · Cited by 159
Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Martín, J. E. S., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2021) · Nefrología · doi:10.1016/j.nefro.2021.07.010 · Cited by 206
Self-citationIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 152
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Dwivedi, S., & Sikarwar, M. S. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2435-8264 · Cited by 165
Wang, Y., Jin, M., Cheng, C. K., & Li, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238927 · Cited by 151
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
New strategies to improve clinical outcomes for diabetic kidney disease
Forst, T. M., Mathieu, C., Giorgino, F., Wheeler, D. C., Παπάνας, Ν., Schmieder, R. E., Halabi, A., Schnell, O., Streckbein, M., & Tuttle, K. R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02539-2 · Cited by 101
Obesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis
Xie, Z., Tong, S., Chu, X., Feng, T., & Geng, M. (2022) · Kidney Diseases · doi:10.1159/000524475 · Cited by 111
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 93
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
“Changes in UACR likely reflect concomitant changes in endothelial function and renal function that may in turn be mediating the cardiovascular benefit [28], but independent of mean systolic blood pressure.”
BackgroundRossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A. Z., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14558 · Cited by 76
Roles of Gut Microbial Metabolites in Diabetic Kidney Disease
Fang, Q., Liu, N., Zheng, B., Guo, F., Zeng, X., Huang, X., & Ouyang, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.636175 · Cited by 75
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Information and consensus document for the detection and management of chronic kidney disease
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Escalada, J., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.003 · Cited by 82
Self-citationLin, Y., Wang, T.-H., Tsai, M., Wu, V. C., Tseng, C.-J., Lin, M., Li, Y., Chang, C., Chou, T., Tsai, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01793-9 · Cited by 57
Lui, D. T. W., Au, I. C. H., Tang, E. H. M., Cheung, C., Lee, C., Woo, Y. C., Wu, T., Tan, K. C. B., & Wong, C. K. H. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101510 · Cited by 46
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Albiglutide Tanzeum SC, qw T2DM 2014 (withdrawal 2018) [72,73]”
Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly
Fadah, K., Hechanova, L. A., & Mukherjee, D. (2022) · International Journal of Angiology · doi:10.1055/s-0042-1751234 · Cited by 56
Dong, S., & Sun, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032199 · Cited by 37
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i39.5691 · Cited by 42
Li, X., Jiang, X., Jiang, M., Wang, Z., Zhao, T., Cao, S.-M., & Li, Q. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02184-y · Cited by 41
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 38
Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria
D’Marco, L., Universidad Cardenal Herrera-CEU, C. U., Guerra, X., Viejo-Boyano, I., Lopez-Romero, L. E. F., Yugueros, A., Bermúdez, V., & Universidad Simón Bolívar, F. D. C. D. L. S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.102 · Cited by 39
Self-citationYuan, D., Sharma, H., Krishnan, A., Vangaveti, V., & Malabu, U. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14776 · Cited by 41
Tuttle, K. R., Bain, S. C., Bosch‐Traberg, H., Khunti, K., Rasmussen, S., Sokareva, E., & Cherney, D. Z. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.028 · Cited by 32
Filippatos, G. S., Anker, S. D., Pitt, B., McGuire, D. K., Rossing, P. R., Ruilope, L. M., Butler, J., Jankowska, E. A., Michos, E. D., Farmakis, D. T., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac054 · Cited by 32
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Kelly, M., Lewis, J., Rao, H., Carter, J., Portillo, I., & Beuttler, R. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2737 · Cited by 29
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
“Renal parameters (eGFR and ACR) were unchanged after 12 months of treatment, confirming the renal safety of GLP1-RAs which were demonstrated to prevent the onset of macroalbuminuria and slow the decline of eGFR (39).”
BackgroundVanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
“7,17,29 In patients with type 2 diabetes mellitus (T2DM) and CKD, the FLOW trial recently demonstrated that GLP1-RA treatment with semaglutide delayed CKD progression and reduced both cardiovascular and kidney mortality risk by 24%.”
The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis
Sasaki, T., Giang, S. M.-L., Wu, J., Yokoo, T., Gallagher, M., Bellomo, R., & Wang, Y. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf193 · Cited by 41
Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Afşar, B., Hornum, M., Afşar, R. E., Ertuğlu, L. A., Ortíz, A., Covic, A. C., van Raalte, D. H., Cherney, D. Z. I., & Kanbay, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.016 · Cited by 30
Abu‐Freha, N., Yitzhak, A., Shirin, H., Nevo-Shor, A., Abu-Jaffar, J., Abu-Rafe, S., Afianish, Y., Cohen, D. L., & Bermont, A. (2024) · Endoscopy · doi:10.1055/a-2419-3875 · Cited by 32
Verde, L., Lucà, S., Cernea, S., Sulu, C., Yumuk, V., Jenssen, T. G., Savastano, S., Sarno, G., Colao, A., Barrea, L., et al. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00500-9 · Cited by 32
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 27
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 26
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
Multifaceted relationship between diabetes and kidney diseases: Beyond diabetes
Esposito, P. B., Picciotto, D., Cappadona, F., Costigliolo, F., Russo, E., Macciò, L., & Viazzi, F. C. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i10.1450 · Cited by 26
Perdomo, C. M., García-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 23
Al-Ghamdi, S., Abu‐Alfa, A. K., Alotaibi, T., AlSaaidi, A., AlSuwaida, A., Arıcı, M., Ecder, T., El-Koraie, A., Ghnaimat, M., Hafez, M. H., et al. (2023) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s363133 · Cited by 22
Das, S., Rajeswari, V. D., Venkatraman, G., Elumalai, R., Sivaraman, D., & Ramanathan, G. (2023) · Translational research · doi:10.1016/j.trsl.2023.11.002 · Cited by 23
Lee, J., Hong, S.-W., Kim, M.-J., Moon, S. J., Kwon, H., Park, S. E., Rhee, E.-J., & Lee, W.-Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1293 · Cited by 20
Re-thinking diabetic nephropathy: Microalbuminuria is just a piece of the diagnostic puzzle
Ceccarelli, D. C., Paleari, R., Solerte, B., & Mosca, A. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.11.009 · Cited by 22
Buzea, A., Manu, P., Dima, L., & Correll, C. U. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2147425 · Cited by 20
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 24
Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?
Buades, J. M., Craver, L., y Pino, M. D. D. P., Prieto‐Velasco, M., Ruiz, J. C., Salgueira, M., de Sequera, P., & Vega, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132943 · Cited by 25
Sun, L., Wu, Y., Hua, R., & Zou, L. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2113797 · Cited by 18
Meta‐analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus
Mahmoud, F., Mullen, A. B., Sainsbury, C. A. R., Rushworth, G. F., Yasin, H., Abutheraa, N., Mueller, T., & Kurdi, A. B. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.13997 · Cited by 19
Albuminuria, Forgotten No More: Underlining the Emerging Role in CardioRenal Crosstalk
Romero-González, G. A., Rodríguez, N., Cañameras, C., Paúl-Martínez, J., Urrutia-Jou, M., Troya, M. I., Soler-Majoral, J., Graterol, F., Sánchez-Baya, M., Martínez, J. C., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030777 · Cited by 27
Arshad, A., Sarween, N., & Sharif, A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.029 · Cited by 20
Targeting Glomerular Hemodynamics for Kidney Protection
Savedchuk, S., Phachu, D., Shankar, M., Sparks, M. A., & Harrison‐Bernard, L. M. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.003 · Cited by 18
GLP-1R agonists: recent advances, current gaps, and future challenges
Saran, A., Raisinghani, R., Paliwal, S., & Sharma, S. K. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11195-6 · Cited by 19
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
Li, R., She, D., Ye, Z., Fang, P., Zong, G., Zhao, Y., Hu, K., Zhang, L., Lei, S., Zhang, K., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s353717 · Cited by 15
Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
Martínez-Hernández, S. L., Muñoz‐Ortega, M. H., Ávila‐Blanco, M. E., Pizaño, M. Y. M., & Ventura‐Juárez, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102828 · Cited by 17
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease
Feng, A., Yin, R., Xu, R., Zhang, B., & Yang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559026 · Cited by 29
Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
Aslam, B., Zafar, M. D. B., Changez, M. I. K., ABDULLAH, M., Safwan, M., QAMAR, B., SHINWARI, A., & Sanjana, R. A. I. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04101-5 · Cited by 21
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Bhushan, B., Granata, D., Kaas, C. S., Kasimova, M. A., Ren, Q., Cramer, C. N., White, M. D., Hansen, A. M. K., Fledelius, C., Invernizzi, G., et al. (2022) · Chemical Science · doi:10.1039/d1sc06844j · Cited by 14
Martos, N., Vergara, A., Llorens-Cebrià, C., Motto, A. E., Martínez-Díaz, I., Gonçalves, F., Garcias-Ramis, M. M., Allo-Urzainqui, E., Narváez, A., Bermejo, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1415879 · Cited by 13
Self-citationThe impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy
Abu‐Freha, N., Levi, Z., Nevo-Shor, A., Guterman, R., Elhayany, R., Yitzhak, A., Yovel, D. Z., Cohen, D. L., & Shirin, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111900 · Cited by 15
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0814 · Cited by 19
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 15
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 12
Rodzoń-Norwicz, M., Kogut, P., Sowa-Kućma, M., & Gala‐Błądzińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146662 · Cited by 12
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Kuang, Z., Hou, N., Kan, C., Han, F., Qiu, H., & Sun, X. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03355-6 · Cited by 10
Yasmin, F., Aamir, M. B., Najeeb, H., Atif, A. R., Siddiqui, A. H., Ahsan, M. N., Moeed, A., Ali, S. H., Tahir, H. M., & Asghar, M. S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001180 · Cited by 14
Overhydration: A cause or an effect of kidney damage and how to treat it
Szymczak, A., Kusztal, M. A., & Krajewska, M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/132035 · Cited by 9
Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
Kim, S., An, J. N., Song, Y. R., Kim, S. G., Lee, H., Cho, A., & Kim, J.-K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273004 · Cited by 10
Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease
Lin, W.-R., Liu, K., Ling, T., Wang, M., & Lin, W. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.352 · Cited by 9
Cao, Y., Cao, S., Zhao, J., Zhao, J., Zhao, Y., & Liu, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1387993 · Cited by 7
Cherney, D. Z. I., Drzewiecka, A., Folkerts, K., Lévy, P., Millier, A., Stephen Morris, A., Pochopień, M., Roy‐Chaudhury, P., Sullivan, S. D., & Mernagh, P. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2451526 · Cited by 7
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
Rodríguez-Miguel, A., Fernández‐Fernández, B., Ortíz, A., Gil, M., Rodríguez‐Martín, S., Ruiz‐Hurtado, G., Fernández-Antón, E., Ruilope, L. M., & de Abajo, F. J. (2024) · Pharmaceuticals · doi:10.3390/ph17101299 · Cited by 9
Self-citationShepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 7
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
Surrogate endpoints in diabetic kidney disease: current perspectives and future directions
Cao, C., Zhang, J., Ma, T., Miao, J., & Sun, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1557813 · Cited by 6
Rico-Fontalvo, J. E., Ciudin, A., Correa‐Rotter, R., Diaz-Crespo, F. J., Bonanno, C., Lecube, A., Daza-Arnedo, R., Morales, E., Quiroga, B., Lorca, E., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.06.013 · Cited by 11
Self-citationHolt, S. G., Koornneef, E. J., Obaidli, A. A. K. A., Hubbert, L., & Nicholson, L. K. (2024) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s481121 · Cited by 6
Chatzis, D., Kolokathis, K., Magounaki, K., Chatzidakis, S., Avramidis, K., Leopoulou, M., Angelopoulos, T. P., & Doupis, J. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.92 · Cited by 7
Zhang, J., Xian, T., Wu, M., Li, C., Wang, W., Man, F., Zhang, X., Wang, X., Pan, Q., & Guo, L. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-002237 · Cited by 6
Multi‐target Drugs to Treat Metabolic Diseases
Lillich, F. F., Goorani, S., Proschak, E., & Imig, J. D. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch13 · Cited by 6
Nomenclature of renal involvement in diabetes mellitus: unify to manage diversity
Marqués, M., Portolés, J. M., Fernández, C. M., Ortíz, A., & Navarro‐González, J. F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1533011 · Cited by 7
Self-citationSemaglutide: a game changer for metabolic diseases?
Milluzzo, A., Manuella, L., & Sciacca, L. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00083 · Cited by 8
Rajagopal, D., Rashid, S. A., Prasad, M., & Fareed, M. (2024) · Cureus · doi:10.7759/cureus.65910 · Cited by 12
A Changing Perspective for Treatment of Chronic Kidney Disease
Garibotto, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173840 · Cited by 5
Nugroho, P., Lydia, A., Soewondo, P., Suhardjono, S. S., Timan, I. S., Harimurti, K., & Ali, Z. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2577271 · Cited by 6
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16434 · Cited by 7
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
Lian, K., Zhang, K., Kan, C., Hou, N., Han, F., Sun, X., Qiu, H., & Guo, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122801 · Cited by 6
Metadata
- Authors
- Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., Navarro-Pérez, J., & Gorgojo-Martinez, J. J.
- Affiliations
- Universitat de València (ES)
- Universitat Autònoma de Barcelona (ES)
- Unidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Universidad de La Laguna, 38200 Tenerife, Spain
- IIS-Fundación Jimenez Diaz UAM and School of Medicine, Universidad Autonoma de Madrid, 28040 Madrid, Spain
- Nephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, Spain
- CAP Sant Pere, ABS Reus 1, 43202 Tarragona, Spain
- Unidad de Endocrinología y Nutrición, Fundación Hospital Alcorcón, 28922 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-03-30
- Volume
- 9
- Issue
- 4
- Pages
- 947
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7231090
- OpenAlex
- W3014018229
- Cited by
- 144
- References
- 72
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 23 · 2023: 29 · 2022: 38 · 2021: 23 · 2020: 2
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Hispana (submittedVersion)
- Funders
- Boehringer Ingelheim
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Amicus Therapeutics
- Fresenius Medical Care North America
- Novo Nordisk
- Astellas Pharma
- Servier
- Sanofi Genzyme
- Instituto de Salud Carlos III (RD16/0009, RD16/0009/0022)
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, diabetic nephropathy, type 2 diabetes, renal protection, glycemic control, macroalbuminuria, glomerular filtration rate decline, renin-angiotensin system inhibitors, proteinuria, weight loss, cardiovascular outcomes, renal replacement therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.